FerenciP,LockwoodA,MullenK., 2002.Hepatic encephalopathy definition, nomenclature, diagnosis,Hepatology 35 716 -21
Lizardi-CerveraJ,AlmedaP,GuevaraL,UribeM., 2003.Hepatic encephalopathy: a review,Ann Hepatol 2 122 -30
LuniaMK,SharmaBC,SachdevaS., 2013.Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and lowgrade hepatic encephalopathy,Hepatol Int 7 268 -73
RiordanSM,WilliamsR, 1997.Treatment of hepatic encephalopathy,N Engl J Med 337 473 -9
BustamanteJ,RimolaA,VenturaPJ, 1999.Prognostic significance of hepatic encephalopathy in patients with cirrhosis,J Hepatol 30 890 -5
MortensenPB, 1992.The effect of oral administrated lactulose on colonic nitrogen metabolism and excretion,Hepatolgy 16 1350 -6
ClausenMR,MortensenPB, 1997.Lactulose, disaccharides and colonic flora,Clinical consequences. Drugs 53 930 -42
OjettiV,LauritanoEC,BarbaroF, 2009.Rifaximin pharmacology and clinical implication,Expert Opin Drug Meta Toxicol 5 675 -82
De'MeloRT,CharneskiL,HilasO, 2008.Rifaximin for the treatment of hepatic encephalopathy,Am J Health Syst Pharm 65 818 -822
Als-NielsenB,GluudLL,GluudC, 2004.Non absorbable disaccharides for hepatic encephalopathy: systemic review of randomized trials,BMJ 328 1046 -
GerardL,GareyKW,DuPontHL, 2005.Rifaximin: a non-absorbable rifamycin antibiotic for use in non-systemic gastrointestinal infections,Expert Rev Anti Infect Ther 3 201 -11
SharmaBC,SharmaP,LuniaMK,SrivastavaS,GoyalR,SarinSK, 2013.A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy,Am J Gastroenterol 108 1458 -63
EltawilKM,LaryeaM,PeltekianK,MolinariM., 2012.Rifaximin vs conventional oral therapy for hepatic encephalopathy: A metaanalysis,World J Gastroenterol 18 767 -77
JiangQ,JiangXH,ZhengMH,JiangLM,ChenYP,WangL, 2008.Rifaximin versus non-absorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis,Eur J Gastroenterol Hepatol 20 1064 -70
NguyenMH,WhittemoreAS,GarciaRT,TawfeekSA,NingJ,LamS, 2004.Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis,Clin Gastroenterol Hepatol 2 820 -4
SanakaMR,OngJP,MullenKD, 2003.Challenges of designing hepatic encephalopathy treatment trials,Hepatology 38 527 -8
GluudLL,DamG,BorreM,LesI,CordobaJ,MarchesiniG, 2013.Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?,Metab Brain Dis 28 221 -5
StahlJ, 1963.Its diagnostic, prognostic, and therapeutic significance,Ann Intern Med 58 1 -24
ConnHO,LeevyCM,VlahcevicZR,RodgersJB,MaddreyWC,SeeffL, 1977.Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial,Gastroenterology 72 573 -83